Loading
companiesCompany
Granza Bio
Granza Bio is turning the natural attack particles that killer immune cells fire at their targets into programmable medicines that can re-arm exhausted immune cells against cancer.
Overview
Granza Bio builds on the discovery of supramolecular attack particles, the cytotoxic granules that cytotoxic T cells and natural killer cells release to kill targets, and engineers them into programmable therapeutics that deliver localised cell killing and re-arm exhausted immune cells, with applications from cancer to autoimmunity. The company is an Oxford-linked spin-out based in San Francisco and is preclinical; no sourced financing rounds are recorded.
Headquarters
San Francisco, CA, US
Funding
All startupsStartupYC W24
Investors
Type
Stage
Startup · Y Combinator Winter 2024
Website
Similar pages
- CompanySynsoryBio
Shares Y Combinator, Cytokines & engineered cytokines and the tag yc.
- CompanyAluna
Shares Y Combinator and the tag yc.
- CompanyMednet (theMednet)
Shares Y Combinator and the tag yc.
- CompanyAlixia
Shares Y Combinator and the tag yc.
- CompanyVelorum Therapeutics
Shares Y Combinator and the tag yc.
- CompanyDelee
Shares Y Combinator and the tag yc.
- CompanyResistanceBio (Viosera Therapeutics)
Shares Y Combinator and the tag yc.
- CompanySerinus Biosciences
Shares Y Combinator and the tag yc.